CIN-107
Phase 2Small molecule
AstraZenecaCIN-107 is one of 71 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
CIN-107
AstraZenecaPhase 2
Winrevair
Merck & Co.Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Salbutamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension2 trials
Metformin1 trial
Function1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CIN-107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company